You are here

Genmab

Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years

Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years

Motley Fool

specialty medicines

Flag link:

Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma

Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma

Fierce Pharma

non-Hodgkin's lymphoma

Flag link:

Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand

Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand

Motley Fool

Multiple Myeloma

Flag link:

Gilead licenses bi-specific tech from Danish biotech Genmab

Gilead licenses bi-specific tech from Danish biotech Genmab

BioPharma Dive

Gilead Sciences

Flag link:

Novartis stops PhIII trial of Genmab's Arzerra after buying rights from GSK

Novartis stops PhIII trial of Genmab's Arzerra after buying rights from GSK

Fierce Biotech

pemphigus vulgaris

Flag link:

J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex

J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex

Fierce Biotech

Multiple Myeloma

Flag link:

J&J positions blockbuster contender daratumumab for a multiple myeloma showdown

J&J positions blockbuster contender daratumumab for a multiple myeloma showdown

Fierce Biotech

Multiple Myeloma

Bristol-Myers Squibb

Flag link:

Novo Nordisk ties the R&D knot with Genmab, and they're not focused on cancer

Novo Nordisk ties the R&D knot with Genmab, and they're not focused on cancer

Fierce Biotech

Flag link:

Novartis files leukemia drug Arzerra in the EU

Novartis files leukemia drug Arzerra in the EU

BioPharma Dive

chronic lymphocytic leukemia

Flag link:

Genmab shares rise on cancer drug's FDA license application

Genmab shares rise on cancer drug's FDA license application

Yahoo/Reuters

Multiple Myeloma

Flag link:

Amgen hands off an IL-15 drug--strings attached--for upstart effort on celiac disease

Amgen hands off an IL-15 drug--strings attached--for upstart effort on celiac disease

Fierce Biotech

Flag link:

JNJ launches PhII lymphoma study for daratumumab

JNJ launches PhII lymphoma study for daratumumab

Fierce Biotech

non-Hodgkin's lymphoma

Flag link:

J&J hands over $25M milestone for daratumumab progress

J&J hands over $25M milestone for daratumumab progress

Fierce Biotech

Flag link:

Glaxo, Genmab report phase III ofatumumab study did not meet primary endpoint

Glaxo, Genmab report phase III ofatumumab study did not meet primary endpoint

The Fly on the Wall

large B-cell lymphoma

Flag link:

Genmab earnings boosted by Janssen collaboration

Genmab earnings boosted by Janssen collaboration

Yahoo/Reuters

Flag link:

Denmark's Genmab expands biotech collaboration with Janssen

Denmark's Genmab expands biotech collaboration with Janssen

Reuters

Duobody antibodies

Flag link:

Milestone payment triggers Genmab guidance increase

Milestone payment triggers Genmab guidance increase

Yahoo/Reuters

Flag link:

GSK/Genmab file Arzerra for first-line CLL

GSK/Genmab file Arzerra for first-line CLL

Pharma Times, UK

chronic lymphocytic leukemia

Flag link:

Genmab announces positive results for sclerosis drug candidate

Genmab announces positive results for sclerosis drug candidate

Reuters

multiple sclerosis

Flag link:

GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)

GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Yahoo/Globe Newswire

chronic lymphocytic leukemia

Flag link: